Key result
CMR T2-mapping and 18FDG PET-CT synergistically identify active cardiac sarcoidosis and monitor treatment response.
Why the study?
The review aimed to synthesize current knowledge regarding imaging of inflammation in cardiac sarcoidosis to aid in differentiating active from chronic, silent disease.
What is the role of CMR and 18FDG-PET-CT in diagnosing and monitoring inflammation in cardiac sarcoidosis?
Systematic Review
What is the role of CMR and 18FDG-PET-CT in diagnosing and monitoring inflammation in cardiac sarcoidosis?
The hybrid application of CMR and 18F-FDG PET-CT has evolved as the standard procedure for detecting active inflammation and monitoring therapeutic response in cardiac sarcoidosis.
Answers are grounded in this paper and cite their sources.
Supports hybrid CMR-PET protocols as standard for cardiac sarcoidosis; systematic review strengthens evidence for synergistic detection and monitoring.
Purpose of the Review The purpose of this paper is to review the current knowledge regarding imaging inflammation in cardiac sarcoidosis (CS). Recent Findings Noninvasive imaging methods like cardiac magnetic resonance (CMR) and 18-fluorodeoxyglucose ( 18 FDG) positron-emission tomography-computed tomography (PET-CT) scans have emerged as the most important modalities in diagnosing and monitor therapy efficacy in CS. The differentiation between an active and a chronic, silent clinical state is crucial for decision making. T1- and T2-mapping by CMR provide a unique opportunity to discriminate normal and diseased myocardium by detecting myocardial edema and fibrosis. While T1-mapping is sensitive to fibrosis and edema, T2 is primarily influenced by tissue water content. Increased 18-fluorodeoxyglucose ( 18 FDG) uptake in positron-emission tomography-computed tomography (PET-CT) scan is a hallmark feature of CS and defines active inflammation. Therefore, the hybrid application of both CMR and 18 FDG-PET-CT scans has evolved as the standard procedure to detect CS and monitor the therapeutic response. Summary Imaging inflammation in CS is basically performed by CMR T2-mapping and 18 FDG uptake in PET-CT scan. Both are reliable methods in identifying active CS and follow up therapy and can be used synergistically. Additionally CMR provides further prognostic insights by late gadolinium enhancement that increases the risk for malignant arrhythmia and for relapse after therapy weaning.
No takes yet. Share an insight, caveat, or question.
Treiber et al. (2024) conducted a systematic review in Cardiac sarcoidosis. Cardiac magnetic resonance (CMR) and 18FDG PET-CT was evaluated. Cardiac magnetic resonance T2-mapping and 18FDG PET-CT scans synergistically identify active cardiac sarcoidosis and reliably monitor therapeutic response.
Synapse has enriched 10 related papers. Consider them for comparative context: